Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.

@article{Findling2007VenlafaxineIT,
  title={Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.},
  author={Robert L. Findling and Laurence Lee Greenhill and Nora Mcnamara and Christine A. Demeter and Lisa A Kotler and Mary Ann O'riordan and Carolyn J. Myers and M. D. Walter Reed},
  journal={Journal of child and adolescent psychopharmacology},
  year={2007},
  volume={17 4},
  pages={433-45}
}
OBJECTIVE The objectives of this pilot study were to explore the changes in symptom severity, tolerability, and the pharmacodynamics of venlafaxine treatment in youths with attention-deficit/hyperactivity disorder (ADHD). METHODS This was a 2-week, open-label, outpatient trial of venlafaxine in children and adolescents, ages 5-17 years, with ADHD. Three dosing strata, 0.5, 1.0, and 2.0 mg/kg per day, were examined. ADHD symptom severity and improvement assessments included the ADHD Rating… CONTINUE READING